A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
about
Advances in Skeletal Dysplasia GeneticsMeclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasiaAdvances in research on and diagnosis and treatment of achondroplasia in China.Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytesRole of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models.FGFR3/fibroblast growth factor receptor 3 inhibits autophagy through decreasing the ATG12-ATG5 conjugate, leading to the delay of cartilage development in achondroplasiaA Ser252Trp mutation in fibroblast growth factor receptor 2 (FGFR2) mimicking human Apert syndrome reveals an essential role for FGF signaling in the regulation of endochondral bone formation.Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.Craniosynostosis: molecular pathways and future pharmacologic therapy.Height matters-from monogenic disorders to normal variation.Advances in treatment of achondroplasia and osteoarthritis.Current Care and Investigational Therapies in Achondroplasia.Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia.HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.Emerging targeted drug therapies in skeletal dysplasias.A novel FGFR1-binding peptide exhibits anti-tumor effect on lung cancer by inhibiting proliferation and angiogenesis
P2860
Q28261525-7B62B185-79F9-4C3E-9F47-F41C41C7BFE8Q28535920-CF3A4BCF-BF49-43C8-8CA6-17C793FD3AB7Q34377947-2A028EBB-F7F8-4526-8B0C-593372CCF537Q35152836-D9168C5A-90F7-4807-AED4-79E78853E811Q35755137-3CF5A2A8-564B-4947-B273-4E7D41F71368Q36777218-1895950A-A7B5-41BE-8CCA-F3AB4EF2FD32Q37525589-58B0E8C9-7782-4467-80A1-C96BCC16EF9FQ37661012-3D98C2C2-65E8-494B-8AE0-D7678AA6FE28Q38068256-24EA9E73-EA68-434A-8E42-89F3BE14AE15Q38075771-418860F9-BF37-42F1-9B0C-1442F8924D31Q38601075-3A6441D8-9F51-4FB4-80FE-30187793048AQ38948779-8486B835-DAAD-4847-8009-35999CD594DAQ47612372-FEDE220A-8302-4DD5-94ED-735D46DCA342Q50493259-C70A0124-87E4-49C9-80B2-8FC50A491AC7Q52826459-534548BE-08FD-4D6F-9560-35B0CC99D508Q54408207-78C69E68-C7C2-4C32-97D2-28E13A4DC021Q54715218-CB29913D-BDA6-45B1-9432-C34BC337FCCFQ56888932-70A45685-2C51-42D2-8BB8-89FA03A7BC8D
P2860
A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia.
@ast
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia.
@en
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia.
@nl
type
label
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia.
@ast
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia.
@en
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia.
@nl
prefLabel
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia.
@ast
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia.
@en
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia.
@nl
P2093
P2860
P356
P1476
A novel FGFR3-binding peptide ...... human thanatophoric dysplasia
@en
P2093
Chu-Xia Deng
Fengtao Luo
Haiyang Huang
Huabing Qi
Qiaoyan Tan
P2860
P304
P356
10.1093/HMG/DDS390
P50
P577
2012-09-26T00:00:00Z